SMALL SOMATIC MUTATIONS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) IDENTIFIED BY EXOME SEQUENCING
- سال انتشار: 1391
- محل انتشار: دوازدهمین کنگره ژنتیک ایران
- کد COI اختصاصی: CIGS12_1048
- زبان مقاله: انگلیسی
- تعداد مشاهده: 1071
نویسندگان
Universit ¨at M¨unchen, M¨unchen, Germany
Tehran University of Medical Sciences, hematology, oncology and stem cell transplantation research center, Tehran, Iran
Tehran University of Medical Sciences, hematology, oncology and stem cell transplantation research center, Tehran, Iran
Tehran University of Medical Sciences, hematology, oncology and stem cell transplantation research center, Tehran, Iran
چکیده
The t(15;17) translocation which results in the PML/RARA fusion is the disease defining lesion in nearly all cases of acute promyelocytic leukemia (APL). Despite the importance of the PML/RARA fusion for the pathogenesis of APL it is most likely not sufficient to cause leukemia alone. For example, collaborating mutations affecting the FLT3 receptor tyrosine kinase are found in about 20−30% of APL patients. To screen systematically for additional mutations, we performed whole exome sequencing of 3 APL patients. Thereby, we generated at least 5 Gbp of exome sequence for each of the APL samples and for each of the corresponding remission samples. This allowed us to cover at least 80% of RefSeq coding exon positions with a minimum read depth of 10 and at least 75% of RefSeq coding exon positions with minimum read depth of 20. By comparing the APL exome sequence with the remission exome sequence, we screened for small APL-specific genetic variants. We were able to confirm 3 to 5 somatic mutations per patient by Sanger sequencing. These APL specific mutations affected not only known mutational targets in leukemia, such as WT1 and KRAS, but also genes with potential implications in leukomogenesis, such as LYN, encoding a kinase which acts downstream of FLT3, and a novel homeobox gene. Our findings demonstrate that exome sequencing is an efficient method to screen for leukemia specific point mutations and small indels that may collaborate with the PML/RARA fusion during the onset and progression of APL.کلیدواژه ها
Acute promyelocytic leukemia, exom sequencing, somatic mutationمقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.